

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/645,746	MELLO ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Maryam Monshipouri	1656

**All Participants:**

(1) Maryam Monshipouri

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_

(2) Ms. D. Milasincic

(4) \_\_\_\_\_

**Date of Interview:** 25 May 2007

**Time:** \_\_\_\_\_

**Type of Interview:**

Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant  Applicant's representative)

Exhibit Shown or Demonstrated:  Yes  No

If Yes, provide a brief description:

**Part I.**

**Rejection(s) discussed:**

*112 first, new matter, 112 second*

**Claims discussed:**

*4, 18-22, 25-26*

**Prior art documents discussed:**

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*See Continuation Sheet*

**Part III.**

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: the examiner indicated that, in view of applicant's response, the utility rejection is withdrawn. However, claims 18-21 will not be allowable because of new matter issues. She also mentioned that washing conditions in claim 4 should be changed to more stringent conditions based on the support provided in the specification. With respect to claims 25-26 the examiner mentioned that said claims are subject to 112 first rejection because no structure is recited for RDE1 polypeptide (see claim 25) or for the term "a fragment" in claim 26. In response, Ms. Milasincic gave authority to the examiner to cancel claims 18-21, amend claim 4, 22 ( which upon cancelation of claim 21 needs to be written independently) and claims 25-26 in an examiner's amendment.